Just wait until the opening bell starts ringing Wednesday, Dendreon (NASDAQ:DNDN) will be counting their money like Nino Brown from a high-rise penthouse on Cloud 9.  Provenge is a winner and appears to be on its way to become the first approved therapeutic vaccine for any type of cancer. Dendreon shares were halted after they plunged 45% in a two-minute span to $11.81 on Nasdaq in the hour leading up to release of the study results. When trading resumed after hours, the shares rose 130% to a new record high of ...